OVERVIEW

Medical Crossfire®: Emerging Strategies to Optimize and Individualize Pulmonary arterial hypertension (PAH) Treatment is organized by Physicians' Education Resource, LLC (PER).

Release Date: October 31, 2019
Expiration Date: October 31, 2020

Accreditation:
Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
Pulmonary arterial hypertension (PAH) is a devastating progressive disease with a considerable burden on quality of life and eventually leads to right-sided heart failure. Advancements in drug therapy and patient care over the past 10 years have improved the morbidity and mortality rates for patients with PAH. Although new therapies have provided major improvement to quality of life in patients with PAH, there is a continual delay in diagnosis and a need to improve therapeutic selection and strategies in the mission to enhance overall patient care. During this Medical Crossfire®, expert faculty will engage in a multidisciplinary roundtable discussion and dissect cases and address best practices for recognizing, diagnosing, and treating patients with PAH.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Determine the role of PAH in differential diagnosis and the appropriate classification of severity
• Apply PAH classification and patient-specific considerations to selection of therapeutic agents for PAH
• Evaluate the potential impact of emerging treatment data on clinical practice